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32% in ALF patients. All patients with fungal infection had
concomitant bacterial infections. Deterioration in HE after
initial improvement, unresponsive pyrexia, renal failure,
and a high leukocyte count despite antibiotics, were clinical
clues to an underlying fungal infection.
The most common site of infection in our patients was the
respiratory tract. Since two-thirds of all deaths occur within
ﬁrst 72 hours and the median time to positive cultures was
4.5 days in our patients, we advocate prophylactic systemic
antibiotics in all ALF patients at admission according to
local sensitivity patterns. Enteral decontamination regimes
need not be added to systemic antibiotics. Improvement
in neutrophil phagocytosis and killing has been shown
both in-vitro and in-vivo by G-CSF. Recently ammonia has
been shown to directly inhibit neutrophil function in vivo,
and ammonia lowering treatments in ALF are a promising
strategy for the future.
I-52 TIPS (transjugular intrahepatic portosystemic
shunts) in the treatment of complications of portal
hypertension
D.M. Brooks *. Austin Hospital, Heidelberg, Australia
Chronic liver disease and its complications are common
throughout the world. Signiﬁcant regional variation exists,
but hepatitis B and C and alcohol abuse account for
around 90% of cases. Autoimmune chronic active hepatitis,
primary and secondary biliary cirrhosis, hemochromatosis,
Budd Chiari syndrome and other rare conditions make up
the remaining 10%. Risk of death comes from variceal
bleeding, progressive liver failure and hepatoma. Among
the important quality of life issues are management of
ascites and hepatic encephalopathy.
Ideally these patients are treated with liver transplantation
however for many patients this treatment is unsuitable or
unavailable. TIPS can be used to control the complications of
portal hypertension in this group. For best patient outcome
TIPS needs to be combined with best medical management
as part of a multidisciplinary approach. Patient selection
and timing of TIPS are critical to a good clinical outcome.
While TIPS has been available since 1985 its clinical
effectiveness was initially limited by a high rate of shunt
stenosis and occlusion. The introduction of covered TIPS
endoprostheses has signiﬁcantly improved the long term
patency and clinical effectiveness of this procedure.
Concurrent Session 10 Management of
Hepatitis C
I-53 Treatment of chronic hepatitis C in Taiwan
J.H. Kao*. Hepatitis Research Center, Graduate Institute
of Clinical Medicine and Department of Internal Medicine,
National Taiwan University College of Medicine and
National Taiwan University Hospital, Taipei, Taiwan
Chronic hepatitis C virus (HCV) infection is a major
health problem worldwide because of its potential adverse
sequelae including cirrhosis-related complications and
hepatocellular carcinoma (HCC). Taiwan is a country
endemic for HCV infection, and 30% of Taiwanese patients
with chronic liver diseases are attributable to this virus.
The primary goal of treatment for chronic hepatitis C is to
eliminate HCV replication and therefore reduce or prevent
hepatic injury. Furthermore, the ultimate long-term goal of
therapy is to prevent hepatic decompensation, to reduce or
prevent disease progression to cirrhosis and/or HCC, and to
prolong survival of patients.
In Taiwan, interferon (IFN)-based therapy has long been
used to treat chronic hepatitis C. Our earlier pilot study
showed that naive patients with 3 MU of conventional IFN
thrice weekly plus 1,200mg of oral ribavirin daily for 24
weeks had a signiﬁcantly higher sustained virologic response
(SVR) rate than those with no treatment (43% vs. 6%). A
randomized trial also suggested that more than one-third
Taiwanese chronic hepatitis C patients who failed prior
IFN monotherapy could achieve SVR after 24 weeks of re-
treatment with combination therapy, and the response rate
was even higher (53%) in those with IFN 6 MU. A study
from southern Taiwan also conﬁrmed that 6 MU regimen
has better efﬁcacy than 3 MU regimen in terms of virologic
and histological responses. In addition, sustained virologic
response to interferon-based therapy can result in reducing
HCC incidence and improving patient survival. Similar to
Caucasian patients with chronic hepatitis C, a recent
multicenter randomized study in Taiwan has conﬁrmed that
combination of PEG-IFN and ribavirin therapy for 24 weeks
had signiﬁcantly better SVR and lower relapse rate when
compared to IFN and ribavirin therapy in our genotype 1
chronic hepatitis C patient, whereas both regimens can be
recommended for genotype non-1 patients. Although the
recommended treatment for genotype patients is peg-IFN
plus ribavirin for 48 weeks, whether treatment duration of
24 weeks is as effective as standard treatment in genotype 1
patients with a rapid virological response (RVR; seronegative
for HCV RNA at 4 weeks) remains unclear. Two large-scale
randomized trials in Taiwan all showed that genotype 1
patients derive a signiﬁcantly better SVR from 48 weeks
versus 24 weeks of peginterferon/ribavirin even if they
attain an RVR. Both 24 and 48 weeks of therapy can achieve
high SVR rates in genotype 1 patients with low viral loads
and an RVR. In addition, a randomized study showed that
16 weeks and 24 weeks of peg-IFN treatment with weight-
based ribavirin at a dose of 1000 1200mg/day provided
equal efﬁcacy in genotype 2 patients who achieved rapid
virologic response (RVR) at 4 weeks.
Several speciﬁcally targeted antiviral therapies for
hepatitis C (STAT-C) have been designed to directly inhibit
the replication of HCV, and early preclinical data showed
encouraging results. Therefore, combination therapy with a
backbone of peg-IFN plus ribavirin, or perhaps using several
of these small molecules with distinct modes of action and
resistance proﬁles, will be proven useful in the future.
I-54 Optimizing HCV antiviral treatment: reducing
treatment duration
S.S. Lee*. Liver Unit, Faculty of Medicine, University of
Calgary, Calgary, Canada
The current ‘gold standard’ treatment for patients with
chronic hepatitis C consists of pegylated interferon-alfa
(PEG-IFN) + ribavirin, for a duration of 48 weeks for those
with HCV genotype 1 and 4, and 24 weeks for genotypes
2 and 3. However, these rigid treatment durations are
now being questioned in light of new information on viral
kinetic responses during the early phase of treatment.
In particular, those with a rapid viral response (RVR),
deﬁned as undetectability of HCV-RNA at 4wk after onset of
treatment, may only need a shorter duration of treatment
whether they have genotype 1, 2, or 3. Evidence suggesting
a shorter 24-wk course in genotype 1 RVR patients and
12 16 weeks in those with genoytpes 2/3 will be presented.
Although there are several pre-treatment baseline factors
that may predict sustained virological response (SVR), such
as genotype, viral load, presence of advanced ﬁbrosis, body
weight and ethnicity, one of the strongest predictors of SVR
is the presence of RVR. Regardless of genotype (studied
only for genotypes 1, 2, 3), the presence of RVR appears
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to be associated with approximately a 85 90% chance of
SVR. There have also been concerns that RVR may differ
depending on which assay is used. In other words, will using
a very sensitive PCR assay with lower limit of detectability
to approximately 10 IU/mL show the same predictability
as the older assays with a detection limit of 50 IU/mL or
those who use an assay with a limit of 500 IU/mL? Current
evidence seems to suggest that no matter which assay is
used, RVR holds its strong predictive value.
While 24wk in genotype 1 RVR is now accepted and even
recommended in some consensus guidelines, shortening
treatment to 16 in those with RVR and genotypes 2 and
3 remains controversial. The largest study with nearly 1500
patients of genotypes 2 and 3 showed that even those
who achieve RVR would beneﬁt (slightly but signiﬁcantly)
from the full 24wk of treatment compared to only 16 wk.
Further study is needed to better deﬁne those subgroups
with genotype 2 and 3 who may be able to shorten duration
of treatment without compromising the chance of achieving
viral clearance. We also need to study increasing duration
or intensifying treatment in those genotype 2 and 3 patients
who do not achieve RVR (about 1/3 of genotype 2 and 3
patients do not achieve RVR), as their sustained virological
response (SVR) rates are only approximately 50% with 24 wk
of treatment. Finally, we should probably start considering
genotypes 2 and 3 separately rather than lumping together
as a single homogeneous entity. It is clear that they behave
slightly differently in response to treatment.
I-55 Management of chronic hepatitis B and C in
HIV-co-infected patients
T. Piratvisuth*. Songklanagarind Hospital, Prince of Songkla
University, Thailand
Due to sharing the same route of transmission, co-infection
of HIV-HBV or HIV-HCV can occur in some patients.
Co-infection with HBV or HCV accelerates liver disease
progression and increases the risk of liver-related mortality
in HIV-infected patients.
Due to low baseline ALT, high baseline HBVDNA and
decreased HBV-speciﬁc T-cell response in HBV-HIV co-
infected patients, treatment with IFN has low efﬁcacy with
HBeAg loss in 0 20% and less tolerability. IFN treatment
should be considered only in patients with ALT more
than 2 times ULN, HBVDNA less than 7 logs copies/ml
and CD4 count greater than 500 cells/mm3. Anti HBV
agents without effect on HIV such as adefovir dipivoxil or
telbivudine is the treatment of choice for patients who not
require HAART. Lamivudine and tenofovir plus other anti
HIV agent are recommended in patients with CD4 more
than 200 cells/mm3 whom HAART is indicated. In order
to prevent immune reconstitution induced-hepatitis ﬂare,
patients with advanced liver disease and low CD4 count
should be initially treated with lamivudine plus tenofovir
until HBVDNA become undetectable before adding the third
agent of HAART.
Peg-IFN plus ribavirin treatment is the standard treatment
for both HCV mono-infection and HCV-HIV co-infection. As
in mono-infected patients, HCV genotype 2, 3 have better
sustained virological (SVR) than genotype 1 (44 69% vs
11 38% in HIV-coinfected patients treated with Peg/IFN
plus ribavirin). Drug interaction and mitochondrial toxicity
must be carefully monitored through out treatment period
in patient receiving HAART. Didanosine should be avoided
in patients receiving ribavirin. On treatment virological
response have a good predictive of response and may be
used to guide treatment decision.
Concurrent Session 11 Emerging Infectious
Diseases: Pathogen in Animal and Human
I-56 Death and severity of meningococcal disease
inﬂuence of microbial phenotype, host genotype
and environment
R.C. Read*. University of Shefﬁeld, United Kingdom
Across Europe the incidence of meningococcal disease varies
from between 1 per 100,000 up to 14.3 per 100,000
population per annum. The case fatality rate overall
is approximately 8%, but amongst survivors there is a
relatively high frequency of severe sequelae including
hearing impairment, neuro-cognitive abnormalities, severe
skin and soft tissue abnormalities including loss of limbs,
and renal failure. Physicians and paediatricians who treat
meningococcal disease observe a range of severity from
relatively benign disease to severe physiological disruption
leading to death. In general terms, those who present with
meningitis tend to have a better prognosis, whilst those
who present with severe sepsis syndrome have the worst
prognosis. Study of factors associated with the severity
of meningococcal disease is difﬁcult and confounded by
factors such as the sporadic nature of the disease and
marked differences in access to health systems between
individuals. Many studies have shown that the outcome of
meningococcal disease is associated with the phenotype of
the infecting organism. The odds of death from disease are
highest for certain sequence types, for example ST-11/ET-37
complex and ST-32/ET-5 complex. The precise phenotypes
responsible for the enhanced virulence of these sequence
types has not been precisely deﬁned. The major virulence
determinants of Neisseria meningitidis include the polysialic
capsule, LPS immunotypes, sialylation, and outer membrane
proteins including Opa and Opc. Whilst there is no consistent
segregation of virulence determinants in clonal groups asso-
ciated with the most severe disease, organisms expressing
serogroup C have been associated with fatal outcome.
A number of host factors have been identiﬁed as important in
determining severity of disease. Chief amongst these is age
at presentation, with the worst prognosis being associated
with adults. Some of this may be explained by the increasing
sophistication of paediatric intensive care. Twin studies have
indicated that death from severe infectious disease has a fa-
milial component and in the case of meningococcal disease a
large number of studies have been conducted to investigate
the role of genes encoding components of the immune sys-
tem, the inﬂammatory response and coagulation pathways.
The difﬁculty faced by geneticists is that death is the most
easily veriﬁable end point for the purpose of studying ge-
netic modiﬁers of severity of disease. Because of the death
rate of only 8% this means that very small cohorts are avail-
able for study. However, association studies have revealed a
relationship between a number of genes and the likelihood
of death in meningococcal disease. These include Fc
receptors, polymorphisms of plasminogen activator inhibitor
type 1, properdin deﬁciencies, and polymorphisms within
interleukin 1 and the interleukin 1 receptor antagonist.
In several countries, there have been increasing reporting of
isolates of Neisseria meningitidis with reduced sensitivity to
penicillin. Treatment failure has been reported extremely
rarely and studies have failed to demonstrate any
association between reduced penicillin susceptibility and
fatal outcome. Most doctors consider that emergency
treatment of newly-presenting cases with penicillin in the
community is mandatory. Controversially, a recent study
has suggested that treatment in the home with injected
penicillin may be associated with increased severity of
disease. This will be discussed.
